目的分析免疫炎症分子CD276对急性心肌梗死(AMI)患者院内主要不良心血管事件(MACEs)的预测效能,评估CD276对AMI患者近期预后的预测价值。方法97例接受经皮冠状动脉介入治疗(PCI)术的AMI患者,根据住院期间是否发生MACEs分为MACEs组(31例...目的分析免疫炎症分子CD276对急性心肌梗死(AMI)患者院内主要不良心血管事件(MACEs)的预测效能,评估CD276对AMI患者近期预后的预测价值。方法97例接受经皮冠状动脉介入治疗(PCI)术的AMI患者,根据住院期间是否发生MACEs分为MACEs组(31例)和非MACEs组(66例)。收集两组临床资料,采用酶联免疫吸附试验(ELISA)检测血清可溶性CD276(sCD276)水平。比较两组临床资料,采用Logistic回归分析住院期间发生MACEs的危险因素,应用受试者工作特征(ROC)曲线评估sCD276对院内MACEs的预测效能。结果MACEs组年龄>65岁占比74.2%、收缩压(SBP)<100 mm Hg(1 mm Hg=0.133 kPa)占比45.2%、sCD276水平(4.20±0.88)ng/ml、Gensini评分(67.30±22.37)分、肌钙蛋白I(cTnI)水平(37.10±13.55)ng/ml、超敏C反应蛋白(hs-CRP)水平(7.55±2.96)mg/L均高于非MACEs组的50.0%、7.6%、(3.37±0.63)ng/ml、(46.20±21.41)分、(27.10±13.14)ng/ml、(5.54±3.54)mg/L,发病到PCI术时间(17.42±5.16)h长于非MACEs组的(12.30±10.36)h,左心室射血分数(LVEF)(46.10±6.61)%低于非MACEs组的(52.08±7.82)%,差异有统计学意义(P<0.05)。多因素Logistic回归分析显示:Gensini评分高、sCD276水平高、SBP<100 mm Hg、LVEF低是院内MACEs发生的危险因素(P<0.05)。sCD276预测院内MACEs发生的ROC曲线下面积(AUC)为0.674[95%CI=(0.552,0.795),P=0.005<0.05],hs-CRP的AUC为0.680[95%CI=(0.564,0.795),P=0.002<0.05],两个指标的预测效能相当,对比无统计学差异(Z=-0.091,P=0.927>0.05)。sCD276联合LVEF、Gensini评分共同预测院内MACEs发生的预测效能[AUC=0.828,95%CI=(0.743,0.913),P=0.000<0.05]与sCD276单独预测相比更高,差异有统计学意义(Z=-2.542,P=0.011<0.05)。sCD276预测院内MACEs发生的最佳截断值为4.14 ng/ml,约登指数为0.326,特异度为0.810,敏感度为0.516。结论sCD276水平高是AMI患者PCI术后院内MACEs发生的危险因素,对AMI患者PCI术后院内MACEs的发生有预测价值,sCD276≥4.14 ng/ml的AMI患者近期预后更差。展开更多
B7-H3(CD276)is one of the immune checkpoint molecules at the forefront of cancer biology,plays a diverse role in immune regulation and cancer progression,while its immunosuppressive functions enable tumors to escape i...B7-H3(CD276)is one of the immune checkpoint molecules at the forefront of cancer biology,plays a diverse role in immune regulation and cancer progression,while its immunosuppressive functions enable tumors to escape immune detection,its contribution to processes such as angiogenesis,metabolic reprogramming and chemoresistance underscores its broader impact on the tumor microenvironment(TME).These propertiesmake B7-H3 an attractive target for cancer therapy.This perspective discusses the immune and non-immune related functions of B7-H3,the challenges in tapping its therapeutic potential.展开更多
文摘目的分析免疫炎症分子CD276对急性心肌梗死(AMI)患者院内主要不良心血管事件(MACEs)的预测效能,评估CD276对AMI患者近期预后的预测价值。方法97例接受经皮冠状动脉介入治疗(PCI)术的AMI患者,根据住院期间是否发生MACEs分为MACEs组(31例)和非MACEs组(66例)。收集两组临床资料,采用酶联免疫吸附试验(ELISA)检测血清可溶性CD276(sCD276)水平。比较两组临床资料,采用Logistic回归分析住院期间发生MACEs的危险因素,应用受试者工作特征(ROC)曲线评估sCD276对院内MACEs的预测效能。结果MACEs组年龄>65岁占比74.2%、收缩压(SBP)<100 mm Hg(1 mm Hg=0.133 kPa)占比45.2%、sCD276水平(4.20±0.88)ng/ml、Gensini评分(67.30±22.37)分、肌钙蛋白I(cTnI)水平(37.10±13.55)ng/ml、超敏C反应蛋白(hs-CRP)水平(7.55±2.96)mg/L均高于非MACEs组的50.0%、7.6%、(3.37±0.63)ng/ml、(46.20±21.41)分、(27.10±13.14)ng/ml、(5.54±3.54)mg/L,发病到PCI术时间(17.42±5.16)h长于非MACEs组的(12.30±10.36)h,左心室射血分数(LVEF)(46.10±6.61)%低于非MACEs组的(52.08±7.82)%,差异有统计学意义(P<0.05)。多因素Logistic回归分析显示:Gensini评分高、sCD276水平高、SBP<100 mm Hg、LVEF低是院内MACEs发生的危险因素(P<0.05)。sCD276预测院内MACEs发生的ROC曲线下面积(AUC)为0.674[95%CI=(0.552,0.795),P=0.005<0.05],hs-CRP的AUC为0.680[95%CI=(0.564,0.795),P=0.002<0.05],两个指标的预测效能相当,对比无统计学差异(Z=-0.091,P=0.927>0.05)。sCD276联合LVEF、Gensini评分共同预测院内MACEs发生的预测效能[AUC=0.828,95%CI=(0.743,0.913),P=0.000<0.05]与sCD276单独预测相比更高,差异有统计学意义(Z=-2.542,P=0.011<0.05)。sCD276预测院内MACEs发生的最佳截断值为4.14 ng/ml,约登指数为0.326,特异度为0.810,敏感度为0.516。结论sCD276水平高是AMI患者PCI术后院内MACEs发生的危险因素,对AMI患者PCI术后院内MACEs的发生有预测价值,sCD276≥4.14 ng/ml的AMI患者近期预后更差。
文摘B7-H3(CD276)is one of the immune checkpoint molecules at the forefront of cancer biology,plays a diverse role in immune regulation and cancer progression,while its immunosuppressive functions enable tumors to escape immune detection,its contribution to processes such as angiogenesis,metabolic reprogramming and chemoresistance underscores its broader impact on the tumor microenvironment(TME).These propertiesmake B7-H3 an attractive target for cancer therapy.This perspective discusses the immune and non-immune related functions of B7-H3,the challenges in tapping its therapeutic potential.
